Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Companies of Artgen Biotech Group intend to enter the markets of friendly countries

9/7/23 ABIO

Sistema will become the main investor in the SEZ in Mordovia

9/7/23 AFKS

Sollers launched a full cycle of production of Sollers Argo trucks

9/7/23 SVAV

NLMK sold its long product division

9/7/23 NLMK

Fix Price plans to enter the UAE market in 2024

9/7/23 FIXP

Ozon opens a new logistics complex in the Moscow region

9/7/23 OZON

Yandex and Xiaomi released the first joint device

9/7/23 YNDX

Fix Price retail revenue in the first half of the year grew by 2.9%

9/7/23 FIXP

Fix Price has reported for 6 months of 2023

9/7/23 FIXP

Fesco considers plans to build up its fleet in the Baltic Sea

9/7/23 FESH